Strategic Workshops Supporting Pharma’s Future

Richard Withers, Strategic Advisor

How to deliver the degree of holistic and objective understanding that today’s market demands

For any company seeking success, strategic intelligence is crucial.

For the pharma industry, the questions surrounding how to win have become increasingly complex, and the answers even more so. Distilling and prioritising the information crucial to strategy-formation can appear a labrynthine task.

So how do you deliver the degree of holistic – and objective – understanding that today’s circuitous market demands? Should you challenge your existing business model? And how can you prepare for the next disruption?

Breakthrough thinking, we’ve seen, lies in the prioritization of a full Strategic Preparedness Workshop (SPW). The SPW goes far beyond traditional pharma workshops that assess one or a few competitors or helps to clarify the path to an already clear-cut goal. Instead, SPWs align key stakeholders early in the direction setting process via a thorough exploration of the strategic challenges, disruptors, and opportunities facing a company. SPWs give leaders a chance to align, engage, and explore the best strategic approach based on deep knowledge of external as well as internal success factors.

In this paper, we’ll show how SPWs should be run – and why.

DOWNLOAD WHITE PAPER

About the author

Richard Withers Deallus Founder

Richard Withers

Richard founded Deallus in 2004 and brings a strong military intelligence background to the life sciences consulting world. He was essential in forming Deallus’ original vision and understanding the value that CI could bring to pharmaceutical clients. As a strategic advisor he works closely with the leadership team to ensure that we continue to deliver best-in class competitive and strategic intelligence to our clients. Richard is adept at supporting the facilitation of workshops, competitive simulations and direction-setting sessions for our clients.

You may also be interested in…

  • Deallus Announce New Senior Principal

Kevin Bibby joins Deallus as Senior Principal

We are very pleased to welcome Kevin Bibby to our Deallus team as Senior Principal. Kevin brings extensive expertise in commercial strategy to the fold, as well as a deep background in brand and portfolio strategy, product positioning, and workshop facilitation. We look forward to adding his knowledge, skill sets, and collaborative spirit to the team.

  • Leading in a Crisis: Driving Value for Your Customers, Your Organization, and Yourself

Episode 2: Leading in a crisis

Join Peter Hempshall, Deallus CEO, and Rita Numerof, President of Numerof & Associates for Episode 2 of their discussion series - Leading in a crisis. This episode will explore topics around how leaders can manage effectively during a crisis and continue to deliver value for their customers, their organizations, and for themselves. Any business leader eager to explore tactics, best practices, and learning experiences gained from leading in times of uncertainty will find value in this episode.

Remdesivir’s journey and its impact on share price

The COVID-19 pandemic will shape several future market trends within the pharmaceutical industry. In terms of emerging macro trends, one notable impact of COVID-19 has been on the stock market within the healthcare sector, historically considered a safe haven for investors during financial crises. Our infographic plots significant events in Remdesivir’s recent history to contextualize this dramatic story and the seemingly disproportionate impact one product’s journey appeared to have on the overall company stock price.

OnDemand Webinar – Navigating Market Disruption after COVID-19

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussions on ‘Navigating Market Disruption After Covid-19’. This OnDemand webinar discusses how the pandemic has accelerated market shifts already in play, disrupting current business models, and dramatically altering how pharma business will be done in the future.